Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Candesartan Cilexetil Related Compound F Pharmaceutical Secondary Standard, MilliporeSigma™ Supelco™

Catalog No. 111003687 Shop All MilliporeSigma Supelco Products
Change view
Click to view available options
Quantity:
20 mg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
11-100-3687 20 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. 11-100-3687 Supplier MilliporeSigma Supelco Supplier No. PHR202020MG
Only null left
Add to Cart
Add to Cart
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.Candesartan cilexetil is a selective antagonist to Angiotensin II receptors, that plays a crucial role in blood pressure regulation and sodium homeostasis, and is popularly used for the treatment of hypertension, diabetic nephropathy and congestive heart failure.
TRUSTED_SUSTAINABILITY

Specifications

Purity Grade Notes These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
Linear Formula C35H38N6O6
Synonym (1-(Cyclohexyloxycarbonyloxy]ethyl 2-ethoxy-1-{[2′-(2-ethyl-2 H-tetrazol-5-yl)-biphenyl-4-yl]methyl}-1 H-benzimidazole-7-carboxylate
Type Certified Reference Material
Quantity 20 mg
Formula Weight 638.71
Grade Certified Reference Material
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.